Introduction
============

Invasive yeast infections are a major threat to patients, particularly the immunocompromised and critically ill, with high morbidity and mortality.[@b1-idr-11-1659]--[@b5-idr-11-1659] Although *Candida* species remain the major cause of such infections, noncandidal yeast species are increasingly encountered as pathogens.[@b1-idr-11-1659],[@b5-idr-11-1659]--[@b8-idr-11-1659] However, knowledge of the clinical characteristics and epidemiology of these pathogens remains relatively limited.[@b1-idr-11-1659],[@b6-idr-11-1659],[@b9-idr-11-1659] Moreover, data on antifungal susceptibility profiles of noncandidal yeasts are relatively few. Even where antifungal susceptibility was performed, there are no clinical breakpoints (CBPs) established using standard broth microdilution methods to guide interpretation.[@b10-idr-11-1659],[@b11-idr-11-1659] These limitations result in uncertainty in clinical management and best practice use of antifungal drugs.[@b1-idr-11-1659],[@b6-idr-11-1659]

China, as one of the most fast developing countries, also suffers from the challenges of relative lack of epidemiology and drug resistance data for invasive yeast infections.[@b7-idr-11-1659],[@b12-idr-11-1659] To close this knowledge gap and to assist clinical management, the China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study was initiated in 2009, focusing on both invasive candidiasis (IC) and noncandidal infections.[@b7-idr-11-1659] Up to the fifth surveillance year (2014), 65 hospitals from 27 of the 34 provinces in China participated, enabling over 8,000 yeast isolates being collected.

In this study, we summarize the overall comparative species distribution of noncandidal yeast isolates and their antifungal susceptibility to fluconazole and voriconazole as determined by the Clinical and Laboratory Standards Institute (CLSI) disk diffusion methodology.[@b10-idr-11-1659],[@b13-idr-11-1659]

Materials and methods
=====================

Study design and isolates
-------------------------

The CHIF-NET study is a prospective, laboratory-based, multicenter study of invasive yeast infections.[@b7-idr-11-1659] This study comprised data from August 1, 2009, to July 31, 2014, and study inclusion criteria have been described previously.[@b7-idr-11-1659] Each surveillance year, all non-repetitive yeast isolates from eligible patients with invasive infections were forwarded to the central laboratory, the Department of Clinical Laboratory, Peking Union Medical College Hospital, for species confirmative identification and antifungal susceptibility testing. The study was approved by the Human Research Ethics Committee of Peking Union Medical College Hospital (S-263). The quality control strains for identification and antifungal susceptibility testing were *Candida parapsilosis* ATCC 22019 and *Candida krusei* ATCC 6258.

Species identification
----------------------

All yeast isolates were identified to the species level in the central laboratory by sequencing of the fungal rDNA internal transcribed spacer (ITS) regions in year 1[@b7-idr-11-1659] or by an algorithm of matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS, Vitek MS system; bioMérieux, Marcy-l'Étoile, France) supplemented by ITS sequencing.[@b14-idr-11-1659]

Antifungal susceptibility testing
---------------------------------

Susceptibility to fluconazole and voriconazole was determined using the CLSI disk diffusion method,[@b6-idr-11-1659],[@b10-idr-11-1659] and the results were interpreted as per the CLSI M44-S3 document (for fluconazole, susceptible, ≥19 mm; susceptible dose-dependent \[SDD\], 15--18 mm; resistant, ≤14 mm; for voriconazole, susceptible, ≥17 mm; SDD, 14--16 mm; resistant, ≤13 mm).[@b13-idr-11-1659]

Statistical analyses
--------------------

All comparisons were performed using SPSS software version 12.0 (SPSS Inc., Chicago, IL, USA). Comparisons of continuous variables were performed by using the Mann-- Whitney test, and comparisons of categorical variables were performed by using a chi-squared test or Fisher's exact test, as appropriate. A *P*-value of 0.05 was significant.

Results
=======

Isolates and patients
---------------------

Fifty-five of 65 participating hospitals submitted a total of 884 non-repetitive noncandidal yeast isolates from separate patients (the remaining 10 hospitals identified no episodes of noncandidal yeast infection cases during the study period) ([Figure 1](#f1-idr-11-1659){ref-type="fig"}). Of the isolates, 300 (35.5%) were cultured from female patients and 544 (64.5%) from male patients. Patient age ranged from 0 to 91 years (median 58, IQR 30--44).

A total of 38 noncandidal yeast species were identified ([Table 1](#t1-idr-11-1659){ref-type="table"}). By genera, *Cryptococcus* species was most common (77.5% or 654/844 isolates), followed by *Trichosporon* species (74/844, 8.8%), *Rhodotorula* species (44/844, 5.2%), and other uncommon genera (\<4%). At the species level, *Cryptococcus neoformans* was predominant, accounting for over 75.6% of the isolates (638/844), but *Cryptococcus gattii* was rare (7/844, 0.8%). *Trichosporon asahii* was the second commonest species (58/844, 6.9%), followed by *Rhodotorula mucilaginosa* (43/844, 5.1%), *Kodamaea ohmeri* (26/844, 3.1%), and *Saccharomyces cerevisiae* (16/844, 1.9%) ([Table 1](#t1-idr-11-1659){ref-type="table"}).

Although *Cryptococcus* spp. was predominant in all seven geographic regions, its frequency varied from 56.3% in northeast China to 89.4% in southwest China ([Table 2](#t2-idr-11-1659){ref-type="table"}). *Trichosporon* spp. was more prevalent in northwest and south China regions (frequency 21.7% and 20.9%, respectively), *Rhodotorula* spp. was more commonly seen in north and northeast regions (12.5% and 11.3%, respectively), whereas other noncandidal yeast species had a frequency of 16.3% and 15%, respectively, in the south and north China regions ([Table 2](#t2-idr-11-1659){ref-type="table"}).

Species distribution by hospital service
----------------------------------------

Overall, only 7.1% (60/844) and 6.8% (57/844) of the noncandidal yeast isolates were collected from emergency departments and outpatient clinics, respectively, and the majority of isolates (727/844, 86.1%) were cultured from patients in inpatient wards.

Of these 727 isolates, 487 (67.0%) were from inpatients in medical wards, 95 (13.1%) from surgical wards, 92 (12.7%) from patients in intensive care units (ICUs), and 53 (7.3%) from other ward types. Of note, the variation in specimen distribution among different inpatient departments largely stemmed from the proportions of the most common organism, *C. neoformans*, 67.2% (429/638) of which were isolated from medical wards. In comparison, isolate rates of other species from medical, surgical wards, and ICUs exhibited less variation (28%--32.9%).

Species distribution by specimen types
--------------------------------------

In this study, over 50% of the isolates (433/844) were cultured from cerebrospinal fluid (CSF), followed by blood (31.4%), ascitic fluid (4.1%), pus (3.7%), tissue (3%), venous catheter (2.5%), and pleural fluid (1.9%) ([Table 3](#t3-idr-11-1659){ref-type="table"}). The specimen distribution in noncandidal yeast infections was notably different to that in IC, among which blood samples predominated (3,858/8,829 isolates, 43.7% during the same period of time in CHIF-NET), and CSF samples only accounted for \<2% (162/8,829) of the collection (Xiao M et al, unpublished data).

There was a high frequency of *Cryptococcus* spp. in CSF samples (428/433 isolates, 98.8%) ([Table 3](#t3-idr-11-1659){ref-type="table"}), whereas other species were rarely recovered from CSF (four isolates of *T. asahii* and one isolate of *Sporidiobolus* spp.) ([Table 3](#t3-idr-11-1659){ref-type="table"}). *Cryptococcus* spp. were also the most common pathogens identified in blood, pus, tissue, and pleural fluid samples ([Table 3](#t3-idr-11-1659){ref-type="table"}). However, non-CSF clinical samples comprised a broader range of noncandidal pathogens, with a total of 19 species identified from blood and 16 and 12 species from ascitic fluid and pus samples, respectively.

Antifungal susceptibilities
---------------------------

Overall, 576/844 (68.2%) isolates were susceptible to fluconazole, and 15.6% of the isolates (132/844) were fluconazole-resistant ([Table 1](#t1-idr-11-1659){ref-type="table"}). In comparison, voriconazole exhibited superior activity, with 93.7% (791/844) of the isolates being susceptible to the agent and resistance only occurred in 5.7% (48/844) of the cases ([Table 1](#t1-idr-11-1659){ref-type="table"}).

The azole susceptibilities varied between different species and for both the azoles tested. For the most common species, *C. neoformans* and *T. asahii*, 74.1% and 81.0% of the isolates were susceptible to fluconazole, respectively, while both species had susceptibility rates of \>98% to voriconazole ([Table 1](#t1-idr-11-1659){ref-type="table"}). However, all isolates of *R. mucilaginosa* were cross-resistant to fluconazole and voriconazole ([Table 1](#t1-idr-11-1659){ref-type="table"}). Only around half of the other uncommon noncandidal yeast isolates (37/72, 51.4%) were susceptible to fluconazole, and one-fourth (18/72, 25.0%) were fluconazole resistant. However, these species were susceptible to voriconazole (69/72, 95.8%).

Five-year trends
----------------

Over 5 years, the frequency of isolation of *Cryptococcus* spp., *Trichosporon* spp., and other noncandidal yeast spp. varied between 73.6%--82.1%, 5.8%--11.3%, and 6.6%--10.5%, respectively, with no significant trend. However, *Rhodotorula* spp. increased significantly from 1.3% in year 1 to 7.0% in year 5 (*P*\<0.001).

*Cryptococcus* spp. exhibited a significantly decreased fluconazole susceptibility from 90.5% in year 1 to 66.0% in year 5 (*P*\<0.001) ([Figure 2](#f2-idr-11-1659){ref-type="fig"}). In addition, there were no fluconazole-resistant *Trichosporon* species strains in years 1--3, but 21.4% of the strains were resistant in year 4, and 6.3% in year 5 (*P*\<0.001) ([Figure 2](#f2-idr-11-1659){ref-type="fig"}). Other noncandidal species also exhibited decreased susceptibility from 90.5% in year 1 to 66.0% in year 5 (*P*\<0.001) ([Figure 2](#f2-idr-11-1659){ref-type="fig"}).

Discussion
==========

The growing population of immunosuppressed patients and increase in medical interventions have resulted in the rise of invasive fungal infections and emergence of novel opportunistic pathogen species.[@b1-idr-11-1659],[@b4-idr-11-1659],[@b5-idr-11-1659],[@b15-idr-11-1659] Although epidemiology and antifungal susceptibility data on IC, which account for a large proportion of invasive fungal infections, are well established, knowledge of infections caused by noncandidal yeasts remain limited in China.

Of note, the significance of antifungal resistance is well acknowledged in non-*Candida albicans* species and increasing trend in species distribution from *C. albicans* to non-*C. albicans* species.[@b1-idr-11-1659],[@b16-idr-11-1659],[@b17-idr-11-1659] However, similar issues in noncandidal yeast species have been relatively understudied, despite the fact that noncandidal yeast species may be less susceptible to antifungal drugs.[@b1-idr-11-1659],[@b8-idr-11-1659],[@b18-idr-11-1659],[@b19-idr-11-1659] One difficulty in assigning susceptibility is the absence of CBPs for noncandidal yeast species based on broth microdilution methods,[@b10-idr-11-1659],[@b11-idr-11-1659] with epidemiologic cutoff values (ECVs) only developed for *C. neoformans*.[@b20-idr-11-1659] In the CHIF-NET study, CLSI disk diffusion methods were employed, as interpretative criteria have been well studied and verified in the ARTEMIS global surveillance program and provide a less expensive and more flexible antifungal susceptibility testing alternative.[@b6-idr-11-1659],[@b10-idr-11-1659],[@b17-idr-11-1659] Disk diffusion assays have exhibited good correlation with broth microdilution methods.[@b21-idr-11-1659],[@b22-idr-11-1659]

Of the 844 isolates collected, *C. neoformans* was the most common organism (\>75%), predominating in both CNS (\>98%) and bloodstream infections (\~63%). In comparison, non-*C. neoformans* species, including *C. gattii*, were sporadically discovered (\<1%). Although globally *Cryptococcus* spp. cause infections mainly in HIV/AIDS patients,[@b5-idr-11-1659] a large proportion of cryptococcal infections occur in non-HIV infected patients in China[@b23-idr-11-1659] and are predominantly caused by *C. neoformans* ST5/VNI/α genotype.[@b24-idr-11-1659] Although as shown in our previous reports, *Cryptococcus* spp. remained highly susceptible to amphotericin B and 5-flucytosine (\>98% of the isolates had wild-type phenotype to these two agents),[@b24-idr-11-1659] as azoles are still the mainstay of treatment for c ryptococcosis,[@b25-idr-11-1659],[@b26-idr-11-1659] the decreasing trend of susceptibility to fluconazole observed in this study is clinically relevant.

*Trichosporon* spp. was the third most common noncandidal yeast genus reported in the ARTEMIS global study,[@b6-idr-11-1659] and in this study, the second most common. The genus can been found in the environment and is associated with summer-type hypersensitivity pneumonitis mostly reported in Japan.[@b1-idr-11-1659],[@b27-idr-11-1659] Invasive fungal infections caused by *Trichosporon* spp., particularly fungemia, most commonly affect patients with hematological diseases.[@b1-idr-11-1659],[@b19-idr-11-1659] Although the *Trichosporon* spp. was all formerly classified as *Trichosporon beigelii*, molecular assays had reclassified the genus, and *T. asahii* remained most common human pathogenic species.[@b19-idr-11-1659],[@b27-idr-11-1659]

*Rhodotorula* species are also emerging opportunistic pathogens, with a higher prevalence in the Asia-pacific regions (17%) than in other regions (5%--14%).[@b6-idr-11-1659] As found in this study, fungemia is typically the predominant clinical manifestation for *Rhodotorula* infection,[@b28-idr-11-1659] although the species can also cause central nervous system infection.[@b29-idr-11-1659] The major risk factors for *Rhodotorula* infection include patient immunosuppression and the presence of a central venous catheter.[@b28-idr-11-1659],[@b29-idr-11-1659] In addition, the genus is notable because of its intrinsic resistance to both echinocandins, fluconazole, and often to other azoles.[@b1-idr-11-1659],[@b8-idr-11-1659],[@b29-idr-11-1659] Although susceptibility to voriconazole may be variable,[@b1-idr-11-1659] in this study, all *Rhodotorula* isolates were cross-resistant to voriconazole. The frequency of *Rhodotorula* spp., over 95% of which were *R. mucilaginosa*, significantly increased over 5 years.

Other noncandidal yeast species, although accounting for less than 4% of the collection, also exhibited decreased fluconazole susceptibility (susceptible rate of around 50% overall), but remaining susceptible to voriconazole. There are no robust guidelines to inform antifungal therapy for these infections. Better diagnostics coupled with surveillance data such as that from the CHIF-NET study could benefit selection of initial antifungal therapy.

As a limitation of this study, CBPs used for CLSI disk diffusion testing were not species-specific adjusted for non-candidal yeast species, as previously noted.[@b6-idr-11-1659] In addition, only two azole agents were studied, as the CLSI disk diffusion methodology was only established for fluconazole and voriconazole when the CHIF-NET study was initiated.[@b6-idr-11-1659],[@b17-idr-11-1659] Although many noncandidal yeast species, eg, *Cryptococcus*, *Trichosporon*, and *Rhodotorula* species, are echinocandin-resistant, data on susceptibility profiles to a broad range of antifungal agents remain a guide to antifungal therapy testing for such susceptibility, including the newer azoles, echino-candins, amphotericin, and flucytosine, will be undertaken in the next stage of the CHIF-NET study.

Conclusion
==========

Our surveillance provided accurate epidemiology and robust antifungal susceptibility data on noncandidal yeast causing invasive infections in China, which was useful for guiding the selection of adequate antifungal therapy. In addition, the notable trends of decreased fluconazole susceptibility in noncandidal yeast species warranted further continued surveillance and essential stewardship interventions.
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![Noncandidal invasive yeast isolates collected in the five-year China Hospital Invasive Fungal Surveillance Net study.\
**Note:** Seven geographic regions in China were labeled by different colors in the map, and locations of participant hospitals were labeled by red dots.](idr-11-1659Fig1){#f1-idr-11-1659}

![Trends of fluconazole susceptibility over 5 years.\
**Notes:** (**A**) Trends of fluconazole susceptible rate. (***B***) Trends of fluconazole resistant rate.\
**Abbreviation:** CHIF-NET, China Hospital Invasive Fungal Surveillance Net.](idr-11-1659Fig2){#f2-idr-11-1659}

###### 

Species distribution of noncandidal yeast isolates causing invasive infections and azole susceptibility of each species

  Species                          Total     \%         Antifungal susceptibility (%)                                              
  -------------------------------- --------- ---------- ------------------------------- ---------- ---------- ---------- --------- ---------
  ***Cryptococcus*** **spp.**      **654**   **77.5**   **73.7**                        **16.4**   **9.9**    **99.4**   **0.5**   **0.2**
  *Cryptococcus neoformans*        638       76.4       74.1                            16.1       9.7        99.5       0.5       
  *Cryptococcus gattii*            7         0.8        57.1                            28.6       14.3       100                  
  *Cryptococcus laurentii*         4         0.5        50.0                            25.0       25.0       100                  
  *Cryptococcus curvatus*          3         0.4        66.7                            33.3                  100                  
  *Cryptococcus arboriformis*      1         0.1        100                                                   100                  
  *Cryptococcus humicola*          1         0.1                                                   100                             100
  ***Trichosporon*** **spp.**      **74**    **8.8**    **77.0**                        **16.2**   **6.8**    **97.3**             **2.7**
  *Trichosporon asahii*            58        6.9        81.0                            13.8       5.2        98.3                 1.7
  *Trichosporon mucoides*          3         0.4        66.7                            33.3                  100                  
  *Trichosporon japonicum*         3         0.4        33.3                            33.3       33.3       66.7                 33.3
  *Trichosporon asteroides*        3         0.4        100                                                   100                  
  *Trichosporon inkin*             3         0.4        33.3                            33.3       33.3       100                  
  *Trichosporon dermatis*          1         0.1        100                                                   100                  
  *Trichophyton interdigitale*     1         0.1                                        100                   100                  
  *Trichosporon jirovecii*         1         0.1        100                                                   100                  
  *Trichosporon montevideense*     1         0.1        100                                                   100                  
  ***Rhodotorula spp.***           **44**    **5.2**                                               **100**                         **100**
  *Rhodotorula mucilaginosa*       43        5.1                                                   100                             100
  *Rhodotorula diobovatum*         1         0.1                                                   100                             100
  **Other yeast spp.**             **72**    **8.5**    **51.4**                        **23.6**   **25.0**   **95.8**   **2.8**   **1.4**
  *Kodamaea ohmeri*                26        3.1        38.5                            42.3       19.2       100                  
  *Saccharomyces cerevisiae*       16        1.9        87.5                                       12.5       93.8       6.3       
  *Dipodascus capitatus*           7         0.8        71.4                            28.6                  100                  
  *Pichia caribbica*               5         0.6        20.0                            60.0       20.0       80.0       20.0      
  *Arthrographis kalrae*           2         0.2                                                   100        100                  
  *Aureobasidium pullulans*        1         0.1                                                   100        100                  
  *Cyberlindnera rhodanensis*      1         0.1                                                   100        100                  
  *Debaryomyces nepalensis*        1         0.1                                        100                   100                  
  *Trichomonascus ciferrii*        1         0.1                                                   100        100                  
  *Hanseniaspora opuntiae*         1         0.1        100                                                   100                  
  *Kazachstania telluris*          1         0.1                                                   100        100                  
  *Pichia fabianii*                1         0.1        100                                                   100                  
  *Pichia jadinii*                 1         0.1        100                                                   100                  
  *Pichia kluyveri*                1         0.1                                                   100        100                  
  *Pichia manshurica*              1         0.1                                                   100        100                  
  *Pichia sydowiorum*              1         0.1        100                                                   100                  
  *Pseudozyma antarctica*          1         0.1        100                                                   100                  
  *Pseudozyma* spp.                1         0.1        100                                                   100                  
  *Quambalaria cyanescens*         1         0.1        100                                                   100                  
  *Rhodosporidiobolus fluvialis*   1         0.1                                                   100                             100
  *Sporidiobolus* spp.             1         0.1                                                   100        100                  
  **Total**                        **844**   **100**    **68.2**                        **16.1**   **15.6**   **93.7**   **0.6**   **5.7**

**Note:** Bold data represented as summarized data.

**Abbreviations:** R, resistant; S, susceptible; SDD, susceptible dose-dependent.

###### 

Geographic distribution of noncandidal yeast genera in mainland China

  Geographic region   Number of isolates (%)                           
  ------------------- ------------------------ ----------- ----------- ----------
  East                230 (82.1)               15 (5.4)    13 (4.6)    22 (0.1)
  Middle              80 (81.6)                8 (8.2)     1 (1.0)     9 (0.1)
  North               106 (70.7)               19 (12.7)   17 (11.3)   8 (0.1)
  Northeast           45 (56.3)                13 (16.3)   10 (12.5)   12 (0.2)
  Northwest           16 (69.6)                5 (21.7)    0 (0)       2 (0.1)
  South               25 (58.1)                9 (20.9)    2 (4.7)     7 (0.2)
  Southwest           152 (89.4)               5 (2.9)     1 (0.6)     12 (0.1)

###### 

Species distribution by specimen types

  Specimen type                  Number of isolates (%)                                        
  ------------------------------ ------------------------ ------------ ----------- ----------- -----------
  Cerebrospinal fluid            433 (51.3)               428 (98.8)   4 (0.9)                 1 (0.2)
  Blood                          265 (31.4)               169 (63.8)   28 (10.6)   34 (12.8)   34 (12.8)
  Ascitic fluid                  35 (4.1)                 9 (25.7)     13 (37.1)   2 (5.7)     11 (31.4)
  Pus                            31 (3.7)                 11 (35.5)    10 (32.3)   2 (6.5)     8 (25.8)
  Tissue                         25 (3.0)                 21 (84.0)                1 (4.0)     3 (12.0)
  Venous catheter                21 (2.5)                 3 (14.3)     11 (52.4)   2 (9.5)     5 (23.8)
  Pleural fluid                  16 (1.9)                 8 (50.0)     3 (18.8)                5 (31.3)
  Bronchoalveolar lavage fluid   5 (0.6)                  2 (40.0)     2 (40.0)                1 (20.0)
  Hydrarthrosis                  5 (0.6)                               3 (60.0)                2 (40.0)
  Peritoneal dialysate           4 (0.5)                                           2 (50.0)    2 (50.0)
  Bone marrow                    3 (0.4)                  2 (66.7)                 1 (33.3)    
  Bile                           1 (0.1)                  1 (100)                              
